Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
G9a CRISPR/Cas9 KO Plasmid (m): sc-430994
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- G9a CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the G9a genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: G9a Antibody (C-9): sc-515726
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
G9a CRISPR/Cas9 KO Plasmid (m) | sc-430994 | 20 µg | $397.00 |
Overview
Mouse Ehmt2 encodes the histone lysine methyltransferase G9a, a principal writer of H3K9 mono- and dimethylation that helps establish repressive chromatin states across euchromatin. G9a coordinates transcriptional silencing programs involved in embryonic development, lineage commitment, and maintenance of cell identity by partnering with chromatin regulators such as GLP (EHMT1) and heterochromatin-associated factors. Through its effects on chromatin accessibility and gene expression, EHMT2 influences DNA damage responses, replication timing, and epigenetic stability. Dysregulated G9a activity and H3K9me2 patterns are widely studied in the context of tumor biology, neurodevelopmental phenotypes, and inflammatory gene regulation, making Ehmt2 a key node for epigenetics-focused research.
G9a CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Ehmt2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Ehmt2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Ehmt2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish G9a protein expression.
This CRISPR knockout system enables efficient generation of Ehmt2-deficient cell models for investigation of G9a signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Ehmt2 exon(s) critical for G9a function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Ehmt2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by G9a CRISPR/Cas9 KO Plasmid (m) and G9a CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Ehmt2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by G9a HDR Plasmid (m) and G9a HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Ehmt2 homology arms to support homology-directed repair at defined Ehmt2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.